Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR…

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial

RAHWAY, N.J.--(BUSINESS WIRE)--Mar 31, 2025-

Winrevair Shows Promise in Advancing PAH Treatment

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent clinical trials have reinforced the potential of Winrevair (sotatercept) as a breakthrough in pulmonary arterial hypertension (PAH) treatment.

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and hospitalization in patients with a rare form of high blood pressure in the lungs, potentially providing a boost to sales.

Merck's Winrevair Transforms PAH Treatment Landscape with 76% Risk Reduction

Merck’s innovative treatment for pulmonary arterial hypertension (PAH), Winrevair, has demonstrated remarkable efficacy in reducing mortality and morbidity risks by 76%, according to interim results from the phase 3 Zenith trial. This promising outcome prompted the early termination of the study due to its conclusive efficacy, and shortly thereafter, another trial of the first-in-class activin signaling inhibitor followed suit. The Zenith trial …

Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking placebo.